Announcements Trials

Browse Landscape

Phase

Status

Enrolling by invitation 1

Sponsor Class

OTHER 35 INDUSTRY 12 UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

apatinib 3 Drug Therapy 3 icotinib 2 camrelizumab 2 Radiotherapy 2 Etoposide 2 Erlotinib Hydrochloride 2 Cisplatin 2 tislelizumab 1 pembrolizumab 1 aumolertinib 1 anlotinib 1 Sunitinib 1 Radiotherapy, Intensity-Modulated 1 Radiosurgery 1 Radiation 1 Povidone-Iodine 1 Pleurodesis 1 Pemetrexed 1 Nutrition Assessment 1 Methylene Blue 1 Lidocaine 1 Irinotecan 1 Indocyanine Green 1 Immunotherapy 1 Gemcitabine 1 Gefitinib 1 Chemoradiotherapy 1 Celecoxib 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

UNKNOWN × aumolertinib × Thoracic × Clear all

NCT04762459 2022-02-24

APEX

ChineseAMS

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡